Herantis Pharma

1,66

EUR

+0,3 %

Corporate customer

HRTIS

First North Finland

Biotechnology & Pharmaceuticals

Health Care

4.213 investorer følger denne virksomhed

Sammenligne

+0,3%

+36,07%

+10,67%

+1,84%

+5,4%

+6,07%

-24,77%

-77,48%

-83,52%

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Læs mere

Markedsværdi

33,47 mio. EUR

Aktieomsætning

26,26 t EUR

P/E (adj.) (24e)

-6,37

EV/EBIT (adj.) (24e)

-6,38

P/B (24e)

159,37

EV/S (24e)

3.350,73

Udbytteafkast, % (24e)

Coverage

Anbefaling

Akkumulér

Kursmål

2.20 EUR

Opdateret

23.08.2024

Disclaimer

Latest research

Latest analysis report

Released: 23.08.2024

Latest extensive report

Released: 25.06.2024

Finanskalender

6.3

2025

Årsrapport '24

24.4

2025

Generalforsamling '24

21.8

2025

Delårsrapport Q2'25

Risiko

Business risk

Valuation risk

Lav

Høj

ViserAlle indholdstyper

Drug development investment: Value creation through M&As and licensing agreements

Artikelfor 8 timer siden af

Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Video16.12.2024, 11.00

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Selskabsmeddelelse12.12.2024, 14.00

Herantis Pharma’s financial calendar and annual general meeting for 2025

Herantis Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Selskabsmeddelelse10.12.2024, 16.30

Proposals of the Shareholders' Nomination Committee to Herantis Pharma Plc's Annual General Meeting 2025

Herantis Pharma

Video3.12.2024, 12.50

Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024

Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

Herantis Pharma

Analytikerkommentar3.12.2024, 10.21 af

Antti Siltanen

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Analytikerkommentar3.12.2024, 06.52

Life Science Night available on inderesTV

Aiforia Technologies Herantis Pharma Faron Pharmaceuticals

Videopræsentation2.12.2024, 14.00

Life Science Night | December 2, 2024

Welcome to follow Life Science Night on Monday, December 2 at 4:00 pm EET on inderesTV.

Aiforia Technologies Herantis Pharma Faron Pharmaceuticals

Analytikerkommentar12.11.2024, 06.53 af

Antti Siltanen

Part 1 of the Herantis trial completed

Herantis issued a press release on Monday announcing the completion of the Part 1 of the Phase Ib clinical trial of the drug candidate HER-096 in healthy volunteers.

Herantis Pharma

Pressemeddelelse11.11.2024, 15.05

Herantis Pharma has successfully completed the Part 1 of the Phase 1b clinical trial

Herantis Pharma

Pressemeddelelse4.11.2024, 10.00

Herantis Pharma Oyj: Herantis Pharma will present at the BioStock Life Science Summit, November 20

Herantis Pharma

Analytikerkommentar24.10.2024, 05.48 af

Antti Siltanen

Herantis R&D webinar complemented scientific background and roadmap

Herantis organized a webinar on Wednesday to discuss the base research, clinical trial program and financial status of HER-096.

Herantis Pharma

Pressemeddelelse23.10.2024, 05.30

Herantis Pharma: Key messages from today’s R&D webinar

Herantis Pharma

Analytikerkommentar17.10.2024, 05.28 af

Antti Siltanen

Herantis clinical trial started as planned

Herantis issued a press release on Wednesday stating that HER-096 dosing has started in the Phase Ib trial.

Herantis Pharma

Pressemeddelelse16.10.2024, 07.30

Herantis Pharma: HER-096 dosing started in the Phase 1b trial

Herantis Pharma

Pressemeddelelse8.10.2024, 05.00

Herantis Pharma to host R&D webinar on October 23, 2024

Herantis Pharma

Selskabsmeddelelse2.10.2024, 10.15

Composition of Herantis Pharma Plc's Shareholders' Nomination Committee

Herantis Pharma

Probabilities of success in drug development

Artikel26.9.2024, 13.26 af

Antti Siltanen

Probabilities of success in drug development

The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development.

Faron Pharmaceuticals Herantis Pharma Mendus

Analytikerkommentar20.9.2024, 06.10 af

Antti Siltanen